Intense competition and clinical trial failures could be among the headwinds that weigh down the company’s share price in 2017. shares have tumbled over the past year.
Category: Johnson and Johnson
This Dividend Anchor Could Return More Than 23% In 2017
Pfizer has been on a roll lately, recently announcing successful top-line results for its third biosimilar in the last four months. The success of its biosimilar initiatives could potentially give Pfizer a secure foothold in the biosimilars market, which could grow to $20 billion in just three years.
Johnson & Johnson Completes Acquisition of Abbott Medical Optics
The all-cash , and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery and consumer eye health. These product lines will now join with the world-leading ACUVUEA Brand Contact Lenses business, and the combined organization will operate under the brand name Johnson & Johnson Vision .